Sustained Release Drug Delivery System for Dry AMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry age-related macular degeneration (AMD) lack effective therapies, with no sustained release drug delivery systems available for intraocular use, leading to frequent injections and potential side effects, and there is no cure for the prevalent dry form of AMD.
Innovation Solution
A biocompatible sustained release drug delivery system comprising an anti-neovascular agent, such as bevacizumab, is administered intravitreally using a polymeric vehicle like hyaluronic acid or PLGA, providing a therapeutic dose over an extended period to prevent progression from dry to wet AMD without the need for suturing or fixation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for dry AMD are used, then no effective therapy is available, but frequent injections are required leading to potential side effects
Solution Approach 1:
The treatment approach is segmented into two distinct forms: dry AMD treatment (preventing neovascularization) and wet AMD treatment (treating existing neovascularization). This segmentation allows for targeted therapy selection based on disease stage, improving overall treatment effectiveness while avoiding unnecessary interventions.
Solution Approach 2:
The patent applies preliminary action by preventing the progression from dry AMD to wet AMD through early intervention with anti-VEGF agents. By treating the dry AMD stage proactively, the need for more aggressive and frequent treatments later is reduced, thereby minimizing long-term side effects.
2Duration of action of moving object
If sustained release drug delivery system is used, then therapeutic dose is maintained over extended period, but device complexity increases
Solution Approach 1:
A sustained-release drug delivery system acts as an intermediary between the anti-VEGF agent and the ocular tissues. This intermediary system maintains stable drug concentrations over time, extending the duration of therapeutic effect while simplifying the treatment regimen compared to frequent injections.
Solution Approach 2:
The drug delivery system utilizes parameter changes in the release kinetics of the anti-VEGF agent, transitioning from immediate-release to sustained-release profiles. This allows for extended therapeutic coverage while maintaining manageable device complexity through controlled release mechanisms.
3Reliability
If anti-VEGF agents are administered to prevent progression from dry to wet AMD, then neovascularization is reduced, but systemic toxicity may occur
Solution Approach 1:
The treatment employs local quality by administering anti-VEGF agents directly to the ocular region through sustained-release delivery systems. This localized administration ensures high concentrations at the target site for effective neovascularization prevention while minimizing systemic exposure and associated toxicity.
Solution Approach 2:
The sustained-release drug delivery system serves as a local intermediary that confines the anti-VEGF agent primarily to the ocular tissues. This intermediary function allows for effective local treatment while reducing systemic circulation of the drug, thereby minimizing systemic toxic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system effectively delays or prevents the progression of dry AMD to wet AMD, maintaining vision and reducing the risk of neovascularization, with low doses of anti-VEGF agents released over several months, minimizing systemic toxicity and side effects.
Implementation Method 1
A biocompatible sustained release drug delivery system comprising an anti-neovascular agent, such as bevacizumab, is administered intravitreally using a polymeric vehicle like hyaluronic acid or PLGA, providing a therapeutic dose over an extended period
Implementation Method 2
Anti-neovascular agents for treatment of wet AMD include agents which block the action of vascular endothelial growth factor (VEGF) thereby slowing angiogenesis (formation of new blood vessels in the retina) which leads to choroidal neovascularization and loss of vision in wet AMD patients
Data Source
AI summary
Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).